Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2016
At a glance
- Drugs Lutetium-177-IMP 288 (Primary) ; TF 2 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.
- 08 Apr 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 10 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2017 as per ClinicalTrials.gov record.